Literature DB >> 11306473

Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells.

T P Cripe1, E J Dunphy, A D Holub, A Saini, N H Vasi, Y Y Mahller, M H Collins, J D Snyder, V Krasnykh, D T Curiel, T J Wickham, J DeGregori, J M Bergelson, M A Currier.   

Abstract

Exploiting the lytic life cycle of viruses has gained recent attention as an anticancer strategy (oncolysis). To explore the utility of adenovirus (Ad)-mediated oncolysis for rhabdomyosarcoma (RMS), we tested RMS cell lines for Ad gene transduction and infection. RMS cells were variably transduced by Ad. Compared with control cells, RMS cells were less sensitive or even resistant to oncolysis by wild-type virus. RMS cells expressed the Ad internalization receptors, alpha(v) integrins, but had low or undetectable expression of the major attachment receptor, coxsackievirus-Ad receptor (CAR). Mutant Ads with ablated CAR binding exhibited only 5-20% of transgene expression in RMS cells seen with a wild-type vector, suggesting that residual or heterogeneous CAR expression mediated the little transduction that was detectable. Immunohistochemical analysis of archived clinical specimens showed little detectable CAR expression in five embryonal and eight alveolar RMS tumors. Stable transduction of the cDNA for CAR enabled both efficient Ad gene transfer and oncolysis for otherwise resistant RMS cells, suggesting that poor CAR expression is the limiting feature. Gene transfer to RMS cells was increased >2 logs using Ads engineered with modified fiber knobs containing either an integrin-binding RGD peptide or a polylysine peptide in the exposed HI loop. The RGD modification enabled increased oncolysis for RMS cells by a conditionally replicative Ad, Ad delta24RGD, harboring a retinoblastoma-binding mutation in the E1A gene. Thus, the development of replication-competent vectors targeted to cell surface receptors other than CAR is critical to advance the use of Ad for treating RMS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306473

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Cell type- and region-dependent coxsackie adenovirus receptor expression in the central nervous system.

Authors:  Annette Persson; Xiaolong Fan; Bengt Widegren; Elisabet Englund
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

3.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

4.  Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas.

Authors:  Hong Jiang; Candelaria Gomez-Manzano; Ramon Alemany; Diana Medrano; Marta Alonso; B Nebiyou Bekele; E Lin; Charles C Conrad; W K Alfred Yung; Juan Fueyo
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

5.  Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer.

Authors:  Xiaochun Zhang; Bingliang Fang; Radhe Mohan; Joe Y Chang
Journal:  Radiother Oncol       Date:  2012-09-27       Impact factor: 6.280

6.  Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.

Authors:  K Takayama; P N Reynolds; Y Adachi; L Kaliberova; J Uchino; Y Nakanishi; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-10-06       Impact factor: 5.987

7.  A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.

Authors:  Yuko Tsuruta; Larisa Pereboeva; Joel N Glasgow; Daniel T Rein; Yosuke Kawakami; Ronald D Alvarez; Rodney P Rocconi; Gene P Siegal; Paul Dent; Paul B Fisher; David T Curiel
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

8.  Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.

Authors:  Hua-Jung Li; Maaike Everts; Masato Yamamoto; David T Curiel; Harvey R Herschman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 9.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

10.  Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy.

Authors:  Travis B Lewis; Joel N Glasgow; Anya M Glandon; David T Curiel; David G Standaert
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.